# Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

> **NCT01897571** · PHASE1,PHASE2 · COMPLETED · sponsor: **Epizyme, Inc.** · enrollment: 400 (actual)

## Conditions studied

- B-cell Lymphomas (Phase 1)
- Advanced Solid Tumors (Phase 1)
- Diffuse Large B-cell Lymphoma (Phase 2)
- Follicular Lymphoma (Phase 2)
- Transformed Follicular Lymphoma
- Primary Mediastinal Large B-Cell Lymphoma

## Interventions

- **DRUG:** Tazemetostat
- **DRUG:** Prednisolone
- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT01897571
- **Lead sponsor:** Epizyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-13
- **Primary completion:** 2021-08-24
- **Final completion:** 2021-11-02
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01897571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01897571, "Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01897571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*